Tirzepatide Versus Dulaglutide in Heart Disease and Diabetes

A newly listed analysis from the SURPASS CVOT program looks at outcomes in people with type 2 diabetes who also have atherosclerotic cardiovascular disease or heart failure, comparing those treated with tirzepatide against those on dulaglutide, according to the PubMed listing for the paper in the European Journal of Preventive Cardiology.

Both drugs are approved injectable medications for type 2 diabetes, not research peptides. Tirzepatide is a dual GIP and GLP-1 receptor agonist, while dulaglutide acts on the GLP-1 receptor alone. SURPASS CVOT is a large, randomized clinical trial structure built specifically to track cardiovascular outcomes, which matters because regulators and clinicians want direct answers on heart attack, stroke, and heart failure risk, not just blood sugar or weight changes.

At the time of writing, the full text of this analysis sits behind a access restriction, so the specific numbers, hazard ratios, and conclusions are not yet available to summarize here. We will follow this listing and report back once the complete results are accessible, since a head to head cardiovascular comparison between these two agents in a population with existing heart disease could meaningfully shape how clinicians think about treatment choice in diabetes with established cardiovascular involvement.

This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.